Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma.

Tessa GargettM Nazim AbbasPaul RolanJason D PriceKatharine M GoslingAntonio FerranteAndrew RuszkiewiczInes I C AtmosukartoJoseph AltinChristopher R ParishMichael P Brown

Published in: Cancer immunology, immunotherapy : CII (2018)

Lipovaxin-MM was well tolerated and without clinically significant toxicity. Immunogenicity of Lipovaxin-MM was not detected. Partial response and stable disease were observed in one and two patients, respectively.

Keyphrases

dendritic cells
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
oxidative stress
clinical trial
peritoneal dialysis
study protocol
randomized controlled trial
regulatory t cells
drug delivery